Labcorp Unveils First FDA-Approved PTEN Diagnostic to Target Prostate Cancer Treatment#USA#Burlington#Labcorp#Prostate_Cancer#PTEN_Assay
Labcorp Unveils First FDA-Approved PTEN Diagnostic to Target Prostate Cancer Treatment
Labcorp has introduced the VENTANA PTEN (SP218) Assay, the first FDA-approved diagnostic for identifying prostate cancer patients eligible for advanced therapy.
third-news.com
August 4, 2026 at 11:20 AM
Labcorp Unveils First FDA-Approved PTEN Diagnostic to Target Prostate Cancer Treatment#USA#Burlington#Labcorp#Prostate_Cancer#PTEN_Assay